BRCA mutations and pathology in the female genital tract

Current Diagnostic Pathology

Volumn 10, Issue 4, 2004, Pages 326-335

  Weinreb, I ^a   Colgan, T J ^b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

BRCA germline mutation; Fallopian tube carcinoma; Familial ovarian cancer; Prophylactic salpingo oophorectomy; Serous adenocarcinoma

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

CARCINOGENESIS; CLINICAL GENETICS; CYSTADENOCARCINOMA; CYTOPATHOLOGY; DNA REPAIR; ENDOMETRIUM CARCINOMA; FAMILIAL CANCER; FEMALE GENITAL SYSTEM; GENE FUNCTION; GENE MUTATION; GENETIC PROCEDURES; GERM LINE GENE THERAPY; GYNECOLOGIC DISEASE; GYNECOLOGICAL EXAMINATION; HISTOPATHOLOGY; HUMAN; OCCULT CANCER; ONCOGENE; OVARY CANCER; OVARY CARCINOMA; PERITONEUM CANCER; POPULATION; PREGNANCY; PREVALENCE; REVIEW; SALPINGOOOPHORECTOMY; UTERINE CERVIX CARCINOMA; UTERINE TUBE; UTERINE TUBE CARCINOMA;

EID: 3042757144     PISSN: 09686053     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cdip.2004.03.005     Document Type: Article

References (82)

1. Frank T.S., Manley S.A., Olopade O.I., et al. Sequence analysis of BRCA1 and BRCA2. correlation of mutations with family history and ovarian cancer risk J Clin Oncol. 16:1998;2417-2425
2. Fearon E.R. Human cancer syndromes. clues to the origin and nature of cancer Science. 278:1997;1043-1050
3. Frank T.S., Deffenbaugh A.M., Reid J.E., et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2. analysis of 10, 000 individuals J Clin Oncol. 20:2002;1480-1490
4. Struewing J.P., Hartage P., Wacholder S., et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 336:1997;1401-1408
5. Bandera C.A., Muto M.G., Schorge J.O., et al. BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum. Obstet Gynecol. 92:1998;596-600
6. Kennedy R.D., Quinn J.E., Johnston P.G., Harkin D.P. BRCA1. mechanisms of inactivation and implications for management of patients Lancet. 360:2002;1007-1014
7. Jazaeri A.A., Yee C.J., Sotiriou C., et al. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancer. J Natl Cancer Inst. 94:2002;990-1000
8. Sharan S.K., Morimatsu M., Albrecht U., et al. Embryonic lethality and radiation hypersensitivity mediated by rad51 in mice lacking BRCA2. Nature. 386:1997;804-810
9. Quinn J.E., Kennedy R.D., Mullan P.B., et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res. 63:2003;6221-6228
10. Werness B.A., Eltabbakh G.H. Familial ovarian cancer and early ovarian cancer. biologic, pathologic, and clinical features Int J Gynecol Pathol. 20:2001;48-63
11. Lavie O., Hornreich G., Ben Arie A., et al. BRCA1 germline mutations in women with uterine serous papillary carcinoma. Obstet Gynecol. 96:2000;28-32
12. Tonin P.N., Mes-Masson A.M., Futreal P.A., et al. Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet. 63:1998;1341-1351
13. Frank T.S. Laboratory determination of hereditary susceptibility to breast and ovarian cancer. Arch Pathol Lab Med. 123:1999;1023-1026
14. Sonoda Y., Saigo P.E., Federici M.G., Boyd J. Carcinosarcoma of the ovary in a patient with a germline BRCA2 mutation. evidence for a monoclonal origin Gynecol Oncol. 76:2000;226-229
15. Levine D.A., Lin O., Barakat R.R., et al. Risk of endometrial carcinoma associated with BRCA mutation. Gynecol Oncol. 80:2001;395-398
16. Boyd J., Sonoda Y., Federici M.G., et al. Clinicopathological features of BRCA-linked and sporadic ovarian cancer. J Am Med Assoc. 283:2000;2260-2265
17. Hughes-Davies L., Huntsman D., Ruas M., et al. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell. 115:2003;523-535
18. Zhang H., Somasundarum K., Peng Y., et al. BRCA1 physically associates with tp53 and stimulates its transcriptional activity. Oncogene. 16:1998;1713-1721
19. Connor F., Bertwistle D., Mee P J., et al. Tumorigenesis and a DNA repair defect in mice with truncated BRCA2. Nat Genet. 17:1997;423-430
20. Ramus S.J., Bobrow L.G., Pharoah P.D.P, et al. Increased frequency of tp53 mutations I BRCA1 and BRCA2 ovarian tumours. Genes Chrom Cancer. 25:1999;91-96
21. Thorlacius S., Sigurdsson S., Bjarnadottir H., et al. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet. 60:1997;1079-1084
22. Agoff S.N., Mendelin J.E., Grieco V.S., Garcia R.L. Unexpected gynecologic neoplasms in patients with proven or suspected BRCA1 or 2 mutations. implications for gross examination, cytology, and follow up Amer J Surg Path. 26:2002;171-178
23. Li A.J., Karlan B.Y. Genetic factors in ovarian carcinoma. Curr Oncol Rep. 3:2001;27-32
24. Rahman N., Stratton M.R. The genetics of breast cancer susceptibility. Ann Rev Genet. 32:1998;95-121
25. Narod S.A., Madlensky L., Bradley L., et al. Hereditary and familial ovarian cancer in southern Ontario. Cancer. 74:1994;2341-2346
26. Ford D., Easton D.F., Stratton M., et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in BC families. the BC linkage consortium Am J Hum Genet. 62:1998;676-689
27. Zweemer R.P., Verheijen R.H., Gille J.J., et al. Clinical and genetic evaluation of thirty ovarian cancer families. Am J Obstet Gynecol. 178:1998;85-90
28. Rebbeck T.R. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 18:2000;100s-103s
29. Risch H.A., McLaughlin J.R., Cole D.E., et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 68:2001;700-710
30. King M., Marks J.H., Mandell J.B. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 302:2003;643-646
31. Antoniou A., Pharoah P.D.P., Narod S., et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history. a combined analysis of 22 studies Am J Hum Genet. 72:2003;1117-1130
32. Narod S.A., Risch A., Moslehi R., et al. Oral contraceptives and the risk of hereditary ovarian cancer. N Eng J Med. 339:1998;424-428
33. Narod S.A., Sun P., Ghadirian P., et al. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations. a case control study Lancet. 357:2001;1467-1470
34. Modan B., Hartge P., Hirsh-Yechezkel G., et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and non-carriers of a BRCA1 or BRCA2 mutation. N Eng J Med. 345:2001;235-240
35. Rosenblatt K.A., Thomas D.B. Reduced risk of ovarian cancer in women with a tubal ligation or hysterectomy. The World Health Organization Collaborative study of neoplasia and steroid contraceptives. Cancer Epidemiol Biomarkers Prev. 5:1996;933-935
36. Piek J.M.J., Van Diest P.J., Zweemer R.P., et al. Tubal ligation and risk of ovarian cancer [letter]. Lancet. 358:2001;844
37. Futreal P.A., Liu O., Shattuck-Eidens D., et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science. 266:1994;120-122
38. Zheng W., Luo F., Lu J.J., et al. Reduction of BRCA1 expression in sporadic ovarian cancer. Gynecol Oncol. 76:2000;294-300
39. Dobrovic A., Simpfendorfer D. Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res. 57:1997;3347-3350
40. Shaw P.A., McLaughlin J.R., Zweemer R.P., et al. Histopathologic features of genetically determined ovarian cancer. Int J Gynecol Pathol. 21:2002;407-411
41. Ontario physician's guide to referral for patients with family history of cancer to a familial cancer genetics clinic or genetics clinic. www.oma.org/pcomm/omr/nov/01genetics.htm. Accessed November 28th 2003.
42. Werness B.A., Ramus S.J., Whittemore A.S., et al. Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations. Hum Pathol. 31:2000;1420-1424
43. Pharoah P.D., Easton D.F., Stockton D.L., et al. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. Cancer Res. 59:1999;868-871
44. Ben David Y., Chetrit A., Hirsh-Yechezkel G., et al. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol. 20:2002;463-466
45. Gotlieb W.H., Friedman E., Bar-Sade R.B., et al. Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumours. J Natl Cancer Inst. 90:1998;995-1000
46. Lu K.H., Garber J.E., Cramer D.W., et al. Occult ovarian tumours in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol. 18:2000;2728-2732
47. Ravid A., Barshack I., Hirsh-Yechezkel G., et al. Immunohistochemical analyses of sporadic and familial (185delAG carriers) ovarian cancer in Israel. Eur J Cancer. 36:2000;1120-1124
48. Collins N., McManus R., Wooster R., et al. Consistent loss of the wild-type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene. 10:1995;1673-1675
49. Johannsson O., Ostermeyer E.A., Hakansson S., et al. Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden. Am J Hum Genet. 58:1996;441-450
50. Tonin P., Moslehi R., Green R., et al. Linkage analysis of 26 Canadian breast-ovarian cancer families. Hum Genet. 95:1995;545-550
51. Tonin P., Wever B., Offit K., et al. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med. 11:1996;1179-1183
52. Friedman L.S., Szabo C.L., Ostermeyer E.A., et al. Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families. Am J Hum Genet. 57:1995;1284-1297
53. Tong P., Stimpfl M., Reinthaller A., et al. BRCA1 gene mutations in sporadic ovarian carcinomas. detection by PCR and reverse transcriptase allele-specific oligonucleotide hybridization Clin Chem. 45:1999;976-981
54. Schubert E.L., Lee M.K., Mefford H.C., et al. BRCA2 in American families with four or more cases of breast or ovarian cancer. recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2 Am J Hum Genet. 60:1997;1031-1040
55. Rose P.G., Shrigley R., Weisler G.L. Germline BRCA2 mutation in a patient with fallopian tube carcinoma. a case report Gynecol Oncol. 77:2000;319-320
56. Zweemer R.P., Van Diest P.J., Verheijen R.H.M., et al. Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol Oncol. 76:2000;45-50
57. Aziz S., Kuperstein G., Rosen B., et al. A genetic epidemiologic study of carcinoma of the fallopian tube. Gynecol Oncol. 80:2001;341-345
58. Sobol H., Jacquemier J., Bonaiti C., et al. Fallopian tube cancer as a feature of BRCA1 associated syndromes [Letter]. Gynecol Oncol. 78:2000;263-264
59. Paley P.J., Swisher E.M., Garcia R.L., et al. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy. a case for recommending hysterectomy at surgical prophylaxis Gynecol Oncol. 80:2001;176-180
60. Moslehi R., Chu W., Karlan B., et al. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet. 66:2000;1259-1272
61. Hornreich G., Beller U., Lavie O., et al. Is uterine papillary carcinoma a BRCA1-related disease? Case report and review of the literature. Gynecol Oncol. 75:1999;300-304
62. Goshen R., Chu W., Elit L., et al. Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome? Gynecol Oncol. 79:2000;477-481
63. Menczer J., Chetrit A., Barda G., et al. Frequency of BRCA mutations in primary peritoneal carcinoma in Israeli Jewish women. Gynecol Oncol. 88:2003;58-61
64. Halperin R., Zehavi S., Langer R., et al. Primary peritoneal serous papillary carcinoma. a new epidemiologic trend? A matched-case comparison with ovarian serous papillary cancer Int J Gynecol Cancer. 11:2001;403-408
65. Eltabbakh G.H., Piver M.S. Extraovarian primary peritoneal carcinoma. Oncology. 12:1998;813-819
66. Muto M.G., Welch W.R., Mok S.C.H., et al. Evidence for a multifocal origin of papillary serous carcinoma of the peritoneum. Cancer Res. 55:1995;490-492
67. Karlan B.Y., Baldwin R.L., Lopez-Luevanos E., et al. Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer. implications for ovarian cancer screening Am J Obstet Gynecol. 180:1999;917-928
68. Schorge J.O., Muto M.G., Welch W.R., et al. Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations. J Natl Cancer Inst. 90:1998;841-845
69. Schorge J.O., Muto M.G., Lee S.J., et al. BRCA1 related papillary serous carcinoma of the peritoneum has a unique molecular pathogenesis. Cancer Res. 60:2000;1361-1364
70. Kaplan E.J., Caputo T.A., Shen P.U., et al. Familial papillary serous carcinoma of the cervix, peritoneum and ovary. a report of the first case Gynecol Oncol. 70:1998;289-294
71. Levine D.A., Federicic M.G., Reuter V.E., Boyd J. Cell proliferation and apoptosis in BRCA-associated hereditary ovarian cancer. Gynecol Oncol. 85:2002;431-434
72. Rebbeck T.R., Lynch H.T., Neuhausen S.L., et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Eng J Med. 346:2002;1616-1622
73. Kauff N.D., Satagopan J.M., Robson M.E., et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Eng J Med. 346:2002;1609-1615
74. Colgan T.J., Murphy K.J., Cole D.E.C., et al. Occult carcinoma in prophylactic oophorectomy specimens. Am J Surg Pathol. 25:2001;1283-1289
75. Leeper K., Garcia R., Swisher E., et al. Pathologic findings in prophylactic oophorectomy specimens in high risk women. Gynecol Oncol. 87:2002;52-56
76. Salazar H., Godwin A.K., Daly M.B., et al. Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst. 88:1996;1810-1820
77. Hartley A., Rollason T., Spooner D. Clear cell carcinoma of the fimbriae of the fallopian tube in a BRCA1 carrier undergoing prophylactic surgery. Clin Oncol. 12:2000;58-59
78. Peyton-Jones B., Olaitan A., Murdoch J.B. Incidental diagnosis of primary fallopian tube carcinoma during prophylactic salpingo-oophorectomy in BRCA2 mutation carrier. Int J Obstet Gynecol. 109:2002;1413-1414
79. Piver M.S., Jishi M.F., Tsukada Y., et al. Primary peritoneal carcinomatosis after prophylactic oophorectomy in women with a family history of ovarian cancer. a report of the Gilda Radner familial ovarian cancer registry Cancer. 71:1993;2751-2755
80. Tobacman J.K.I., Greene M.H., Tucker M.A., et al. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian cancer prone families. Lancet. 2:1982;795-797
81. Colgan T.J. Challenges in the early diagnosis and staging of fallopian-tube carcinomas associated with BRCA mutations. Int J Gynecol Pathol. 00:2003;1-12
82. Colgan T.J., Boerner S.L., Murphy J., et al. Peritoneal lavage cytology. an assessment of its value during prophylactic oophorectomy Gynecol Oncol. 85:2002;397-403